Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Merck
Baxter
Medtronic
Johnson and Johnson

Last Updated: October 1, 2022

Details for Patent: 8,329,648


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,329,648
Title:Methods for treating diabetes and reducing body weight
Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA.sub.1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
Inventor(s): Fineman; Mark (San Diego, CA), MacConell; Leigh (San Diego, CA), Taylor; Kristin (San Diego, CA)
Assignee: Amylin Pharmaceuticals, LLC (San Diego, CA)
Application Number:13/084,757
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,329,648

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No See Plans and Pricing See Plans and Pricing REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 See Plans and Pricing
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE See Plans and Pricing
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No See Plans and Pricing See Plans and Pricing REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
Johnson and Johnson
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.